WaveTec secures investment

Article

In a new round of financing, investor, Burril & Company, has given WaveTec $16.5 million to commercialize its ORA System.

In a new round of financing, Burrill & Company, has given WaveTec $16.5million to commercalize its ORA system.

Tom Frinzi, WaveTec president and CEO, said, "The participation of a new lead investor further validates the scientific and clinical potential of the ORA System, This new capital enables us to further expand our commercial efforts as well as continue product refinement. We’re confident of our leadership in this space and of our ability to help surgeons provide superior refractive cataract outcomes.”

According to the company, the system enables surgeons to optomize results in cataract patients due to enhanced quality wavefront image. It features precision lenses, offering better accuracy and improving outcomes for patients.

Live display of the eye is available in full-field view for quality image captures, meaning surgeons can identify and diagnose measurements. Intraoperative astigmatic correction is guided by a system-aligned, on-demand reticle. This provides axial guidance for toric lens and limbal relaxing incision placement.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.